financetom
Business
financetom
/
Business
/
Southwest Airlines Pilot Arrested Prior to Flight Wednesday, Charged With Driving Under the Influence
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Southwest Airlines Pilot Arrested Prior to Flight Wednesday, Charged With Driving Under the Influence
Jan 16, 2025 2:31 PM

05:14 PM EST, 01/16/2025 (MT Newswires) -- A Southwest Airlines ( LUV ) pilot was removed from one of its jets and arrested in Savannah, Georgia, this week after allegedly boarding the aircraft under the influence of alcohol, authorities and the airline told MT Newswires on Thursday.

The Chatham County Sheriff's Office identified the pilot as David Paul Allsop, age 52 and residing in Bedford, New Hampshire, who was arrested for driving under the influence. Records show he was released on cash bond after being booked and photographed.

In a statement to MT Newswires, a Southwest ( LUV ) spokesperson said, "The employee involved in the situation on Flight 3772 Wednesday morning from Savannah has been removed from duty."

Passengers on the flight leaving Savannah, Georgia, and bound for Chicago were able to board other flights to reach their destinations, the spokesperson said. "We apologize for the disruption to their travel plans. There's nothing more important to Southwest ( LUV ) than the safety of our employees and customers."

Southwest ( LUV ) did not provide the name of the suspect or other details of the arrest, but several media outlets, including CBS News and The Boston Globe, reported police removed him from a Southwest ( LUV ) flight shortly before takeoff around 7 am on Wednesday and with passengers already onboard.

Southwest ( LUV ) shares closed roughly 2% lower on Thursday.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
J&J beats Wall St estimates on strong drug sales ahead of Stelara competition
J&J beats Wall St estimates on strong drug sales ahead of Stelara competition
Jul 18, 2024
(This July 17 story has been corrected to clarify that the CFO did not suggest that pending Stelara insurance contracts would be 'favorable,' in paragraph 4) By Patrick Wingrove and Bhanvi Satija (Reuters) - Johnson & Johnson beat estimates for second-quarter profit and revenue on Wednesday, driven by strong sales of its drugs, including cancer treatment Darzalex and blockbuster psoriasis...
Update: Prime Day Sets Sales Records, Amazon Says
Update: Prime Day Sets Sales Records, Amazon Says
Jul 18, 2024
09:30 AM EDT, 07/18/2024 (MT Newswires) -- (Adds stock movement in second paragraph.) Amazon.com ( AMZN ) said Thursday that its Prime Day 2024 was its biggest ever, with record sales and more items sold during the two-day event than any previous Prime Day. Shares of Amazon ( AMZN ) were up nearly 1% just before the opening bell. Price:...
BRIEF-Amphenol Corporation To Acquire Mobile Networks Businesses From Commscope
BRIEF-Amphenol Corporation To Acquire Mobile Networks Businesses From Commscope
Jul 18, 2024
July 18 (Reuters) - Amphenol Corp ( APH ): * AMPHENOL CORPORATION TO ACQUIRE MOBILE NETWORKS BUSINESSES FROM COMMSCOPE * AMPHENOL CORP ( APH ) - DEAL EXPECTED TO BE ACCRETIVE TO AMPHENOL'S DILUTED EPS IN FIRST FULL YEAR AFTER CLOSING * AMPHENOL CORP ( APH ) - EXPECTS TO FINANCE ACQUISITION THROUGH A COMBINATION OF CASH ON HAND AND...
Teva Pharmaceutical Says Trial of Ajovy to Prevent Episodic Migraine in Children Reaches Primary Endpoint
Teva Pharmaceutical Says Trial of Ajovy to Prevent Episodic Migraine in Children Reaches Primary Endpoint
Jul 18, 2024
09:30 AM EDT, 07/18/2024 (MT Newswires) -- Teva Pharmaceutical Industries ( TEVA ) said Thursday its phase 3 trial assessing Ajovy's effectiveness in preventing episodic migraine in children and adolescents reached its primary endpoint. The drug candidate reached a statistically significant superior efficacy during 12 weeks of treatment compared with placebo, the company said. The safety data was similar to...
Copyright 2023-2026 - www.financetom.com All Rights Reserved